Letter to Gilead on Access to Lenacapavir in Latin America and the Caribbean
December 22, 2025
On Universal Health Coverage Day, December 12, UAEM joined a coalition of organizations, community networks, and activists across Latin America and the Caribbean, alongside international allies, to call on Gilead Sciences to ensure access to lenacapavir in Latin America and the Caribbean.
Lenacapavir is the twice-yearly long acting injectable PrEP (pre-exposure prophylaxis) that could transform the HIV response globally. However, Gilead has failed to file for regulatory approval in most Latin American and Caribbean countries, and most people in Latin America remain excluded from Gilead’s access strategies.
In a letter to Gilead’s CEO, Mr. Daniel O’Day, the coalition outlined the opportunity for Gilead to:
Accelerate the registration of Lenacapavir
Adopt a fair and transparent pricing policy for Latin America
Establish a transparent and constructive dialogue with key stakeholders
Refrain from “evergreening” practices
As the letter states, “Science cannot remain a privilege for the few. Prevention is a right—for everyone, regardless of country, identity, migration status, or economic condition.”